Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients

Rheumatology

Volumn 50, Issue 1, 2011, Pages 189-195

  Southwood, Taunton R ^a   Foster, Helen E ^b   Davidson, Joyce E ^c   Hyrich, Kimme L ^d   Cotter, Catherine B ^a   Wedderburn, Lucy R ^e   Hull, Richard G ^f   Venning, Helen E ^g   Rahman, Joy K ^a   Cummins, Carole L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Arthritis; Child; Disease remission; Drug discontinuations; Etanercept; Juvenile idiopathic arthritis; Methotrexate; Serious adverse event

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BLURRED VISION; CAUCASIAN; CHILD; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; ECZEMA; EPSTEIN BARR VIRUS INFECTION; EXTENDED OLIGOARTHRITIS; FEMALE; FOLLOW UP; GINGIVA DISEASE; GINGIVA INFECTION; HALLUCINATION; HUMAN; INADVERTENT MEASLES, MUMPS AND RUBELLA VACCINATION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENINGOENCEPHALITIS; MENORRHAGIA; MOOD DISORDER; OPTIC NEURITIS; PANIC; POLYARTHRITIS; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SURVIVAL; SYSTEMIC ARTHRITIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; UVEITIS; VACCINATION REACTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS; WITHHOLDING TREATMENT;

EID: 79951717320     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq308     Document Type: Article

References (33)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998;4:381-91.
3. Schmeling H, Mathony K, John V, Keyâer G, Burdach S, Horneff G. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001;60:410-2.
4. Lovell DJ, Giannini EH, Reiff A et al. for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
5. Giannini EH, Ilowite NT, Lovell DJ et al. for the Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
6. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
7. Prince FHM, Twilt M, Ten Cate R et al. Long-term follow-up on effectiveness and safety register of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
8. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor a blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
9. Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-TNF agents in juvenile idiopathic arthritis 2009. Ann Rheum Dis 2009; 68:552-7.
10. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48: 1093-101.
11. Petty RE, Southwood TR, Manners P et al. for the International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;3:390-2.
12. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology Appraisal No. 35 National Institute for Clinical Excellence. 1-24 March 2002. www.nice.org.uk (17 June 2009, date last accessed).
13. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of Improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
14. Clinical safety data management: definitions and standards for expedited reporting. CPMP/ICH/377/95. www.emea.eu.int (25 January 2010, date last accessed).
15. Lovell DJ, Ruperto N, Goodman S et al. for the Pediatric Rheumatology Collaborative Study Group and Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
16. Ruperto N, Lovell DJ, Quartier P et al. for the Paediatric Rheumatology International Trials Organization and Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
17. Ruperto N, Lovell DJ, Cuttica R et al. for the Paediatric Rheumatology International Trials Organisation and Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56: 3096-106.
18. Tauber T, Daniel D, Barash J, Turetz J, Morad Y. Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis. Rheumatology 2005;44:405.
19. Tauber T, Turetz J, Barash J, Avni I, Morad I. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 2006;10:26-9.
20. Armbrust W, Kamphuis SS, Wolfs TW et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004;43:527-9.
21. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
22. Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNF alpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:252-8.
23. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA registry. Ann Rheum Dis 2009;68: 519-25.
24. Hyrich KL, Symmons DPM, Watson KD, Silman AJ. on behalf of the British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
25. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with Juvenile Idiopathic arthritis treated with anti-TNF Pediatr 2006;149:833-6.
26. Saurenmann RK, Levin AV, Rose JB et al. Tumour necrosis factor a inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
27. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44: 1008-11.
28. Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53: 18-23.
29. Reiff A, Takei S, Sadeghi S et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-5.
30. Ruemmele FM, Prieur AM, Talbotec C et al. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004;39:203-6.
31. Wiegering V, Morbach H, Dick A, Girschick HJ. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010;30:801-4.
32. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, Chronopoulou E, Trachana M. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine 2008;42: 293-7.
33. Kimura Y, Pinho P, Walco G et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.